![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
![[thumbnail of Supplementary Information]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Information)
3MB |
| Item Type: | Article |
|---|---|
| Title: | Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study |
| Creators Name: | Hernández-Sánchez, A., González, T., Sobas, M., Sträng, E., Castellani, G., Abáigar, M., Valk, P.J.M., Villaverde Ramiro, Á., Benner, A., Metzeler, K.H., Azibeiro, R., Tettero, J.M., Martínez-López, J., Pratcorona, M., Martínez Elicegui, J., Mills, K.I., Thiede, C., Sanz, G., Döhner, K., Heuser, M., Haferlach, T., Turki, A.T., Reinhardt, D., Schulze-Rath, R., Barbus, M., Hernández-Rivas, J.M., Huntly, B., Ossenkoppele, G., Döhner, H. and Bullinger, L. |
| Abstract: | Balanced rearrangements involving the KMT2A gene (KMT2Ar) are recurrent genetic abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the prognostic impact of different fusion partners. Moreover, prognostic implications of gene mutations co-occurring with KMT2Ar are not established. From the HARMONY AML database 205 KMT2Ar adult patients were selected, 185 of whom had mutational information by a panel-based next-generation sequencing analysis. Overall survival (OS) was similar across the different translocations, including t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 (p = 0.756). However, independent prognostic factors for OS in intensively treated patients were age >60 years (HR 2.1, p = 0.001), secondary AML (HR 2.2, p = 0.043), DNMT3A-mut (HR 2.1, p = 0.047) and KRAS-mut (HR 2.0, p = 0.005). In the subset of patients with de novo AML < 60 years, KRAS and TP53 were the prognostically most relevant mutated genes, as patients with a mutation of any of those two genes had a lower complete remission rate (50% vs 86%, p < 0.001) and inferior OS (median 7 vs 30 months, p < 0.001). Allogeneic hematopoietic stem cell transplantation in first complete remission was able to improve OS (p = 0.003). Our study highlights the importance of the mutational patterns in adult KMT2Ar AML and provides new insights into more accurate prognostic stratification of these patients. |
| Source: | Leukemia |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Date: | 4 July 2024 |
| Official Publication: | https://doi.org/10.1038/s41375-024-02333-4 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
